Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jose Nazari

Clinical Cardiac Electrophysiology Glenview, IL Medical Doctor

NPI 1962502476 CMS profile 270025

2150 Pfingsten Rd Ste 1200, Glenview, IL 60026

Open in the dashboard

General payments

$24,853

474 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$64,282 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jose Nazari of Glenview, IL is reported in the CMS Open Payments database as having received $24,853 across 474 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $64,282 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 57th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,006 139
2024 General $3,614 107
2023 General $2,551 74
2022 General $1,635 42
2021 General $1,537 39
2020 General $3,023 19
2019 General $6,488 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Nazari
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Jose Nazari were reported at $6,006. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Jose Nazari Clinical Cardiac Electrophysiology median Middle half National median
2019 $6,488 $2,361 $585–$8,260 $163
2020 $3,023 $993 $247–$4,351 $114
2021 $1,537 $1,185 $326–$4,739 $132
2022 $1,635 $2,073 $554–$6,789 $149
2023 $2,551 $2,568 $759–$8,159 $160
2024 $3,614 $2,557 $703–$7,403 $164
2025 $6,006 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medical Device Business Services, Inc. $7,150 6 payments
  2. Biosense Webster, Inc. $3,667 40 payments
  3. Medtronic, Inc. $3,179 31 payments
  4. Janssen Pharmaceuticals, Inc $1,524 60 payments
  5. Novartis Pharmaceuticals Corporation $1,483 63 payments
  6. Boston Scientific Corporation $1,110 27 payments
  7. Abbott Laboratories $1,066 15 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $1,008 39 payments
  9. AstraZeneca Pharmaceuticals LP $864 49 payments
  10. Novo Nordisk Inc $559 21 payments
  11. Other $3,244 123 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,626 458 payments
  2. Consulting Fee $8,000 8 payments
  3. Travel and Lodging $2,138 6 payments
  4. Education $90 2 payments
Products named General payments · program years 2019–2025
  1. Carto 3 System $7,692 9 payments
  2. Carto 3 $3,090 29 payments
  3. LEQVIO $1,246 51 payments
  4. XARELTO $966 40 payments
  5. ENTRESTO $607 24 payments
  6. JARDIANCE Diabetes $588 21 payments
  7. OPSUMIT $535 16 payments
  8. WATCHMAN $518 8 payments
  9. JARDIANCE Diabetes $420 18 payments
  10. FARXIGA $360 17 payments
  11. Other $8,244 291 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,277

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$607,890

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

49.1%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 377 $376,624
Xarelto Rivaroxaban Brand 150 $175,908
Multaq Dronedarone Hcl Brand 21 $30,431
Dofetilide Generic 64 $13,540
Flecainide Acetate Generic 129 $4,940
Metoprolol Succinate Generic 171 $2,325
Amiodarone Hcl Generic 106 $1,219
Omeprazole Generic 78 $1,028
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 37 $610
Clopidogrel Clopidogrel Bisulfate Brand 42 $498

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 73 billing codes

Paid by Medicare

$289,882

Medicare's payments for the services billed

Medicare patients

2,381

Average age 80

Services billed

4,276

1,092 women, 1,289 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 63%
Arthritis 52%
Ischemic heart disease 48%
Heart failure 46%
Chronic kidney disease 35%
Diabetes 34%
Cancer 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPSUMIT
  • Janssen Pharmaceuticals, Inc $336
  • Actelion Pharmaceuticals US, Inc. $42
$379 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $272
$272 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $238
$238 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $202
$202 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $119
  • Janssen Pharmaceuticals, Inc $27
$146 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

474 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record